Figure 1From: Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignanciesMaximum reduction in target lesion size. Best change in the sum of the product of diameter (SPD) of target lesions achieved over all restages. One patient with Hodgkin lymphoma had no postbaseline tumor measurements reported and is thus not included in the summary. Analysis excludes the second retreatment for 3 systemic anaplastic large cell lymphoma patients.Back to article page